Genasense Phase 3 melanoma: accrual completes Q1 09
Tesetaxel: Orphan drug designations Q1 09
Tesetaxel results from ongoing U.S. trial H1 09
Genasense EU: “cohort ATU” H2 09
Melanoma AGENDA data: final PFS H2 09
Tesetaxel gastric cancer trial: SPA completed H2 09
Melanoma NDA/MAA H2 09

Genasense is a major commercial opportunity
• Regulatory approvals asap:
• Confirmatory Phase 3: melanoma
• Establish improved dosing schedule
• Named-patient program ensures access
• Pipeline clinical introductions accelerate
• Ongoing partnering activities